Assessment of a Candidate Marker Constituent Predictive of a Dietary Substance-Drug Interaction: Case Study with Grapefruit Juice and CYP3A4 Drug Substrates by Ainslie, G. R. et al.
1521-0103/351/3/576–584$25.00 http://dx.doi.org/10.1124/jpet.114.216838
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 351:576–584, December 2014
Copyright ª 2014 by The American Society for Pharmacology and Experimental Therapeutics
Assessment of a Candidate Marker Constituent Predictive of
a Dietary Substance–Drug Interaction: Case Study with
Grapefruit Juice and CYP3A4 Drug Substrates
Garrett R. Ainslie, Kristina K. Wolf,1 Yingxin Li, Elizabeth A. Connolly, Yolanda V. Scarlett,
J. Heyward Hull, and Mary F. Paine
Curriculum in Toxicology (G.R.A., M.F.P.) and Division of Gastroenterology and Hepatology (Y.V.S.), School of Medicine, and
UNC Eshelman School of Pharmacy (K.K.W., Y.L., E.A.C., J.H.H.), The University of North Carolina, Chapel Hill, North Carolina;
and Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Spokane, Washington (G.R.A.,
M.F.P.)
Received May 21, 2014; accepted August 25, 2014
ABSTRACT
Dietary substances, including herbal products and citrus juices, can
perpetrate interactions with conventional medications. Regulatory
guidances for dietary substance–drug interaction assessment are
lacking. This deficiency is due in part to challenges unique to dietary
substances, a lack of requisite human-derived data, and limited
jurisdiction. An in vitro–in vivo extrapolation (IVIVE) approach to help
address some of these hurdles was evaluated using the exemplar
dietary substance grapefruit juice (GFJ), the candidate marker
constituent 69,79-dihydroxybergamottin (DHB), and the purported
victim drug loperamide. First, the GFJ-loperamide interaction was
assessed in 16 healthy volunteers. Loperamide (16 mg) was ad-
ministered with 240 ml of water or GFJ; plasma was collected from
0 to 72 hours. Relative to water, GFJ increased the geometric mean
loperamide area under the plasma concentration–time curve (AUC)
significantly (1.7-fold). Second, the mechanism-based inhibition
kinetics for DHBwere recovered using human intestinalmicrosomes
and the index CYP3A4 reaction, loperamide N-desmethylation
(KI [concentration needed to achieve one-half kinact], 5.06 0.9 mM;
kinact [maximum inactivation rate constant], 0.386 0.02 minute
21).
These parameters were incorporated into a mechanistic static
model, which predicted a 1.6-fold increase in loperamide AUC.
Third, the successful IVIVE prompted further application to 15
previously reported GFJ-drug interaction studies selected accord-
ing to predefined criteria. Twelve of the interactionswere predicted
to within the 25% predefined criterion. Results suggest that DHB
could be used to predict the CYP3A4-mediated effect of GFJ. This
time- and cost-effective IVIVE approach could be applied to other
dietary substance–drug interactions to help prioritize new and
existing drugs for more advanced (dynamic) modeling and simu-
lation and clinical assessment.
Introduction
Drug-drug interactions (DDIs) due to inhibition of drug-
metabolizing enzymes can produce severe adverse effects, re-
sulting in cautionary statements on drug labels or withdrawal
of the drug from the market (Fujioka et al., 2012). Conse-
quently, regulatory agencies recommend or require thorough
characterization of new drug candidates as both DDI “victims”
and “perpetrators.” Such characterization, spanning from dis-
covery to clinical development, is well defined and generally
harmonized among the various agencies. In contrast, relevant
guidelines are nonexistent for diet-derived products, including
dietary supplements and exotic beverages, which represent an
ever-increasing share of the Western health care market. This
deficiency reflects the relative lack of robust human-derived in
vitro and in vivo data, precluding development of a systematic
approach that would help identify dietary substances as potential
perpetrators of interactions with drugs, as well as prioritize for
clinical evaluation.
As an initial step toward developing an aforementioned ap-
proach, methods used to predict and characterize metabolism-
based DDIs could be extended to dietary substance–drug
interactions. DDI predictions using in vitro enzyme kinetic
parameters have become increasingly more advanced in drug
discovery (Vieira et al., 2014). Mechanistic static models have
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shown success for DDIs localized in the liver, the primary site
of these interactions. However, because diet-derived constitu-
ents generally have a low systemic exposure (due to extensive
presystemic metabolism) but high intestinal exposure, and
most drugs are taken orally, the gut likely represents the
primary site of dietary substance–drug interactions. Accord-
ingly, models that are tailored to processes exclusive to the gut
may be more appropriate for predicting these interactions.
Assessing dietary substance–drug interaction risk poses
additional challenges compared with DDIs. Unlike drugs, di-
etary substances typically are complex mixtures that vary sub-
stantially in phytochemical composition, between both brands
and batches of the same brand (Won et al., 2012). Accordingly, it
has been postulated that “marker” constituents can be iden-
tified and used to predict the effect of the mixture (Won et al.,
2012; National Center for Complementary and Alternative
Medicine, 2013). Ideally, one marker constituent would be
identified. Whether one or a few, such constituent(s) would
enable a simplified and cost-effective means to assess dietary
substance–drug interaction risk during the drug discovery
process.
Grapefruit juice (GFJ) is an extensively studied perpetrator
of dietary substance–drug interactions. When consumed in
usual volumes, the “GFJ effect” is limited to the intestine, as
evidenced by the general lack of an effect on the pharmaco-
kinetics of intravenously administered drugs and on the
terminal half-life of orally administered drugs. Most victim
drugs share three requisite traits: they are orally adminis-
tered, have a low to intermediate absolute bioavailability, and
undergo CYP3A4-mediated first-pass metabolism in the in-
testine (Bailey et al., 2013). GFJ contains a chemical class of
constituents, furanocoumarins, which are potent mechanism-
based inhibitors of CYP3A4 (Paine et al., 2006a), a prominent
drug-metabolizing enzyme expressed in both the intestine
and liver (Paine et al., 2006b). 69,79-Dihydroxybergamottin
(DHB), a typically abundant furanocoumarin in the juice, may
represent a single marker constituent predictive of whole
juice based on the following key properties/observations: the
mechanism-based inhibition (MBI)–associated constant
(KI; 1–5 mM) is well below/within concentrations measured in
GFJ (0.2–52 mM) (De Castro et al., 2006); the onset of peak
effect, defined as the maximum loss of CYP3A4 protein in human
intestine-derived cell monolayers (Caco-2) (Paine et al., 2005),
is predictive of that in healthy volunteers administered GFJ
(Lown et al., 1997); the polarity relative to other furanocoumarins
enables straightforward quantification in both GFJ and biologic
matrices; and an authentic standard is commercially available
that is not cost prohibitive.
In the present work, an in vitro–in vivo extrapolation (IVIVE)
approach using DHB as a marker constituent of the exemplar
dietary substance GFJ was applied to a purported victim drug
that had not been described in the literature. Loperamide, a
m-opioid receptor agonist, was selected as the test victim drug
based on the aforementioned criteria. In addition, anecdotal re-
ports suggest an abuse potential when taken at supratherapeutic
doses with GFJ (Daniulaityte et al., 2013), substantiating
investigation of the interaction liability. The aim of this study
was to test the proposed approach of using a marker con-
stituent to predict the effect of a mixture by (1) confirming
a CYP3A4-mediated dietary substance–drug interaction in-
volving GFJ and loperamide in healthy volunteers; (2) ob-
taining MBI kinetic parameters for the marker constituent,
DHB, using loperamide N-desmethylation by human intes-
tinal microsomes as the index reaction; (3) applying a mech-
anistic static model using DHB to predict the GFJ-loperamide
interaction; and (4) applying the model to previously re-
ported CYP3A4-mediated GFJ-drug interaction studies to
evaluate robustness of both the marker constituent and
IVIVE method. Results will aid in the selection of marker
constituents to assess dietary substance interaction liability
with candidate and marketed drugs and help prioritize these
drugs for more advanced modeling and, ultimately, clinical
evaluation.
Materials and Methods
Human intestinal microsomes (HIMs), pooled from 13 donors of
mixed gender (7 male, 6 female), were purchased from XenoTech, LLC
(Lenexa, KS). Plasma pooled from multiple donors (mixed gender,
distribution unknown) was purchased from Biological Specialty Cor-
poration (Colmar, PA). Loperamide hydrochloride, D6-loperamide,
N-desmethylloperamide, and D3-N-desmethylloperamide were purchased
from Toronto Research Chemicals, Inc. (North York, ON, Canada).
DHBwas purchased fromCaymanChemical (AnnArbor,MI). Psoralen,
NADPH, and dimethylsulfoxide (DMSO) were purchased from Sigma-
Aldrich (St. Louis, MO). Liquid chromatography–tandem mass spec-
trometry (LC-MS/MS)–grade acetonitrile, water, methanol, and formic
acid were purchased from Thermo Fisher Scientific (Waltham, MA).
Human Subject Study
Preparation of Grapefruit Juice. Multiple cans of a single brand
(Minute Maid, Sugar Land, TX) and lot of frozen GFJ concentrate were
purchased from a local grocery store. The concentrates were thawed
and pooled, and an aliquot was saved for measurement of DHB by high-
performance liquid chromatography (Paine et al., 2006a). The pooled
concentrate was diluted with water to achieve a “double-strength”
juice (DHB final concentration ∼70 mM) to maximize the likelihood
of observing an interaction. The diluted juice was divided into
240-ml aliquots and stored at 220°C and protected from light until
needed.
Clinical Protocol and Participants. The University of North
Carolina Office of Human Research Ethics/Biomedical Institutional
Review Board and Clinical and Translational Research Center (CTRC)
Oversight Committee reviewed and approved the protocol. Potential
subjects provided written informed consent and Health Insurance
Portability and Accountability Act authorization before screening at the
CTRC, which consisted of amedical history, physical examination, liver
function tests, and complete blood count. All women underwent a serum
pregnancy test.
Study Design and Procedures. A prospective, randomized, two-
phase, open-label crossover study was conducted at the CTRC (Fig. 1).
Prior to the first study phase, the participants were asked to abstain
from all fruit juices for 1 week before and during the study, and from
alcohol and caffeinated beverages the evening before each study day.
Participants were admitted to the CTRC the evening before each study
phase. Vital signs (blood pressure, temperature, pulse, respirations)
and oxygen saturation were obtained upon admission and monitored
periodically throughout the in-patient portion of each phase. All women
underwent a repeat serum pregnancy test. After an overnight fast,
each participant was administered 16 mg of loperamide (Mylan Inc.,
Canonsburg, PA) with 240 ml of water or GFJ. Blood (7 ml) was
collected from an indwelling intravenous catheter before and 0.5, 1, 2, 3,
4, 5, 6, 8, 10, and 12 hours after loperamide administration. Blood was
centrifuged within 1 hour of collection; plasma was removed and stored
at 280°C pending analysis for loperamide and the primary CYP3A4-
mediated metabolite, N-desmethylloperamide, by LC-MS/MS (see
below). Subjects continued to fast until after the 4-hour blood collection,
after which meals and snacks, devoid of fruit juices/products and
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caffeinated beverages, were provided. After the 12-hour blood collection,
subjects were discharged. Subjects returned to the CTRC as out-
patients for blood draws at 24, 36, 48, and 72 hours after loperamide
administration. The two phases were separated by at least 2 weeks.
Concurrent with the blood collections, dark-adapted pupil di-
ameter, the most sensitive index of opioid effect, was measured using
a NeurOptics VIP-200 pupillometer with a resolution of 0.1 mm (San
Clemente, CA). Pupil diameter was obtained at least in triplicate,
with coefficients of variation #2.8%. The light intensity of the room,
measured by a Sper Scientific 840021 light meter (Scottsdale, AZ),
was always ,1 lux. As a positive control for the miotic effect,
9 subjects (5 men, 4 women) were administered a “morphine challenge”
the evening of the first phase. Morphine sulfate (0.07 mg/kg i.v.;
Hospira Inc., Lake Forest, IL) was administered as a 5-minute
infusion via a syringe pump. Pupil diameter was measured before and
5, 10, 20, 30, 60, 90, and 120 minutes after infusion. Subjects were in
the supine position and were monitored with an automated blood
pressure cuff and pulse oximeter during the infusion and for 2 hours
thereafter. Vital signs were monitored concurrent with pupil di-
ameter measurement. Supplemental oxygen was available if oxygen
saturation decreased to ,94%. The opioid antagonist, naloxone (In-
ternational Medication Systems Ltd., South El Monte, CA), and anti-
emetic agent, promethazine (Goldline Laboratories, Inc., North Wales,
PA), were available if needed.
Determination of Mechanism-Based Inhibition Kinetic
Parameters for DHB
Time- and concentration-dependent inhibition of CYP3A4 activity by
DHB in HIMs was assessed as described previously (Paine et al., 2004),
except that N-desmethylloperamide formation was used as the index
reaction. In brief, loperamide and DHB were dissolved in DMSO to yield
working solutions of 5 and 2 mM, respectively. Primary incubation
mixtures consisted of HIMs (5mg/ml), DHB (0, 2.5, 5, 10, and 30mM), and
potassium phosphate buffer (0.1 M, pH 7.4). The mixtures were equil-
ibrated at 37°C for 5minutes before initiating the reactions with NADPH
(1 mM final concentration), yielding a final volume of 80 ml; the final
concentration of DMSO was ∼1% (v/v). At designated times from 0 to
5 minutes, an aliquot (10 ml) was removed and diluted 20-fold into
secondary incubation mixtures containing loperamide and NADPH
(1 mM), yielding a final loperamide concentration of 60 mM. Secondary
reactions were terminated after 20 minutes by transferring 100 ml to
a 96-well plate containing 300 ml of acetonitrile/0.1% (v/v) formic acid and
internal standard (0.5 mM D3-N-desmethylloperamide). Plates were
centrifuged (2000g for 10 minutes at 4°C), and 200 ml of supernatant
was transferred to clean plates. The contents were dried under heated
nitrogen (50°C), reconstituted in 200 ml of 95% water:5% acetonitrile:
0.1% formic acid (v/v/v) (initial chromatographic conditions), and
analyzed for N-desmethylloperamide by LC-MS/MS (see below).
Quantification of Loperamide and N-Desmethylloperamide
Human Plasma. Plasma (50 ml) was added to methanol (70 ml)
containing internal standard (4.3 nM D6-loperamide and D3-N-
desmethylloperamide), then precipitated with 360 ml of methanol.
The mixtures were vortexed for 5 minutes and centrifuged (3000g for
10minutes at 4°C). Calibration (0.1–25 nM) and quality control (0.75, 4,
and 12 nM) solutions were prepared using authentic standards and
blank human plasma. Sample (5 ml) was injected onto an Aquasil C18
(2.1  50 mm, 5 mm particle size) analytical column (Thermo Fisher
Scientific). Analytes were eluted with a binary gradient consisting of
water/0.1% (v/v) formic acid (mobile phase A) and acetonitrile/0.1% (v/v)
formic acid (mobile phase B) at a flow rate of 0.75 ml/min. Initially,
mobile phase B was held at 20% for 0.4 minute, then increased linearly
to 95% for 3.6 minutes. Mobile phase B was held at 95% for 0.5 minute,
then returned to initial conditions over 6 seconds and equilibrated.
The total run time was 5 minutes. All eluted solvent was directed to
an API4000 QTRAP triple quadrupole mass spectrometer (AB Sciex,
Framingham, MA). Multiple reaction monitoring mode was used
to detect loperamide (477.3→266.2 m/z), N-desmethylloperamide
(463.2→252.2 m/z), D6-loperamide (483.3→272.2 m/z), and D3-N-
desmethylloperamide (466.3→255.2m/z); collision energy was set to
20 mV for all analytes. Loperamide and N-desmethylloperamide
concentrations were quantified using Analyst software (v1.4.1; AB
Sciex) by interpolation from matrix-matched calibration curves and
quality controls with a linear range of 0.1–25 nM. The calibration
standards and quality controls were judged for batch quality based
on the 2013 Food and Drug Administration guidance for industry
regarding bioanalytical method validation (US Food and Drug
Administration, 2013).
Microsomal Incubations. Calibration (1–1000 nM) and quality
control (2.5, 500, and 800 nM) solutions were prepared using authentic
N-desmethylloperamide standard and HIMs. Sample (5 ml) was in-
jected onto an Aquasil C18 (2.1 50 mm, 5 mm particle size) analytical
column. Chromatographic separation was achieved using the same
high-performance liquid chromatography system and mobile phases as
for plasma. Due to the high buffer and salt content of the microsomal
samples relative to plasma, the binary gradient method was modified.
Initial conditions consisted of 10% mobile phase B held for 1 minute,
then increased linearly to 95% B over 1.5 minutes and held for
0.5minute. The gradientwas returned to initial conditions over 0.1minute
to equilibrate the column. The total run time was 4 minutes. The eluted
solvent was directed to a Sciex API5600 triple quadrupole–time of
flight mass spectrometer. Ionization was achieved with a turbo
electrospray source operated in positive ion mode. The declustering
potential and collision energy were set to 25 V and 30 mV, respec-
tively. N-Desmethylloperamide was quantified using Multiquant
software (v2.1.1; AB Sciex), selecting a fragment ion range of
252.1–252.8 and 255.1–255.8 m/z for N-desmethylloperamide and
D3-N-desmethylloperamide, respectively. As with plasma analysis,
Fig. 1. Clinical study design and procedures. As a positive control for miosis, nine subjects were administered morphine sulfate (0.07 mg/kg i.v.;
5-minute infusion); pupil diameter wasmeasured before and 5, 10, 20, 30, 60, 90, and 120minutes after infusion. After an overnight fast, subjects (n = 16)
were administered 16 mg of loperamide with either 240 ml of water (control) or grapefruit juice (treatment). Blood and dark-adapted pupil diameter
measurements were obtained before and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours after loperamide administration on the first day of each study phase.
Subjects returned as outpatients for blood draws and pupil diameter measurements at 24, 36, 48, and 72 hours after loperamide administration. The two
phases were separated by at least 2 weeks.
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all calibration standards and quality control samples were judged
for batch quality based on the 2013 Food and Drug Administration
guidance (US Food and Drug Administration, 2013).
Data Analyses
Pharmacokinetic and Pharmacodynamic Analysis. Pharma-
cokinetic and pharmacodynamic outcomes were recovered via non-
compartmental methods using Phoenix WinNonlin (v6.3; Certara,
St. Louis, MO).
Pharmacokinetics. The maximum concentration (Cmax), time to reach
Cmax (Tmax), and last measured concentration (C72h) were obtained directly
from the plasma concentration–time profiles. The terminal elimination
rate constant (lz) was determined by linear regression of the terminal
portion of the log-transformed concentration-time profile using at least
three data points. The terminal half-life (t1/2) was calculated as ln(2)/lz.
Area under the plasma concentration–time curve (AUC) from time 0 to
72 hours (AUC0-72h) was determined using the trapezoidal method with
linear up/log down interpolation. TheAUC fromtime0 to infinity (AUC0-inf)
was calculated as the sum of AUC0-72h and C72h/lz. The oral clearance of
loperamide (Cl/F) was calculated as the ratio of dose to AUC0-inf. The
metabolite-to-parent AUC ratio [(AUCm/AUCp)0-72h] was calculated as the
ratio of the AUC0-72h of N-desmethylloperamide to that of loperamide.
The primary pharmacokinetic outcomewas the ratio of loperamideAUC0-inf
in the presence of GFJ to that in the absence of GFJ (AUCGFJ/AUC).
Pharmacodynamics. Baseline pupil diameter was obtained at time
0, and miosis was determined as the decrease in pupil diameter from
baseline. The area under the effect (miosis)-time curve from 0 to
72 hours (AUEC0-72h) was calculated by the linear trapezoidal method
with an adjustment from the baseline pupil diameter measurement.
The maximum decrease in pupil diameter (Rmax) was obtained directly
from the miosis-time profile.
MBI Kinetic Parameters for DHB. KI (concentration needed to
achieve one-half kinact) and kinact (maximum inactivation rate constant)
were recovered using previously published methods (Paine et al., 2004;
Obach et al., 2007). Final parameter estimates were obtained by
nonlinear least-squares regression using PhoenixWinNonlin and eq. 1:
kinact;app 5
kinact•½DHB
KI 1 ½DHB (1)
where kinact,app denotes the apparent inactivation rate constant at
each inhibitor (DHB) concentration, determined by the slope of the
monoexponential decline in activity. Model fit was evaluated from
visual inspection of the observed versus predicted values, randomness
of the residuals, and standard errors of the parameter estimates. The
efficiency of inactivation was calculated as the ratio of kinact to KI.
Grapefruit Juice–Loperamide Interaction Prediction Using
DHB as a Marker Constituent. The GFJ-mediated increase in
AUC (AUCGFJ/AUC) for loperamide was predicted using DHB as
a marker constituent and a mechanistic static model (eq. 2) for















where Fg denotes the fraction of the dose of victim drug (loperamide)
escaping first-pass extraction in the intestine (0.62), Ig denotes the
concentration of inhibitor (DHB) in the enterocyte (5 mM), and kdeg
denotes the degradation rate constant associated with intestinal
CYP3A4 (0.000481 minute21) (Obach et al., 2007). The Qgut and
Advanced Dissolution, Absorption, and Metabolism (ADAM) models
in Simcyp (v13; Certara) (Yang et al., 2007; Jamei et al., 2009) were
used to estimate loperamide Fg using MDCK cell permeability
(Peff, 0.586  1024 cm/s) (Tran et al., 2004) and recombinant CYP3A4
metabolism data (Km,CYP3A4, 6.3 mM; Vmax,CYP3A4, 1.7 pmol/min per
nanomole CYP3A4) (Kim et al., 2004). The ADAM model was used to
estimate Ig using Caco-2 cell permeability data (Peff, 6.202 1024 cm/s)
(Paine et al., 2005) and a DHB “dose” equal to that in the clinical GFJ-
loperamide interaction study (72.3 mM, or 6.2 mg/240 ml serving). The
fraction of the dose of loperamide absorbed into enterocytes was
assumed to remain unchanged in the presence of GFJ.
Grapefruit Juice–Drug Interaction Predictions with Mar-
keted Drugs Using DHB as a Marker Constituent. The utility of
DHB as a marker constituent predictive of CYP3A4-mediated GFJ-
drug interactions was examined further withmarketed drugs that have
been evaluated in the clinic. Test victim drugs (Table 2) were selected
based on the following criteria: intestinal CYP3A4 substrate, availabil-
ity of human pharmacokinetic data, and availability of Fg. Fg was
obtained, in order of precedence, from liver transplant recipients during
the anhepatic phase of the operation, by the combined intravenous/oral
administration method, or from in vitro–in vivo scaling techniques
(Galetin et al., 2010). Drugs whoseFg valueswere estimated by a fourth
method, which involves GFJ administration (Gertz et al., 2008), were
excluded to avoid bias. Because the static model cannot account for
differences in GFJ administration frequencies, and the DHB concen-
tration in the clinical study juice often was not measured/not reported,
a range of DHB Ig values (0.05, 5, and 50 mM) was used. AUCGFJ/AUC
predictions were made using eq. 2 and evaluated against observations
from the literature. As the GFJ-loperamide interaction study was
powered to detect a 25% change in loperamide AUC0-inf, predicted
AUCGFJ/AUCs were evaluated against observed ratios with a prede-
fined cutoff of 25% to define a successful prediction (Vieira et al., 2014).
Sensitivity Analysis to Assess the Relationship between
DHB Ig, Victim Drug Fg, and the Predicted AUCGFJ/AUC. Due
to the uncertainty in DHB Ig, the variability in GFJ administration
frequency in clinical studies, the uncertainty in victim drug Fg
predictions, and the potential variability in kdeg, AUCGFJ/AUCs were
simulated with increasing Ig, Fg, and kdeg. Simulations were
conducted in Phoenix WinNonlin using eq. 2, with Ig ranging from
0 to 5 mM, Fg from 0.1 to 0.9, and kdeg from 0 to 0.005 minute
21 in
increments of 0.1 mM, 0.05, and 0.0001 minute21, respectively.
Statistical Analyses
Statistical analyses were conducted using SAS (v9.1.3; SAS In-
stitute, Cary, NC).
Clinical Study. The sample size was based on 80% power to
detect a 25% difference in the primary outcome of loperamide,
AUCGFJ/AUC, with an alpha of 0.05. Data are presented as the
geometric mean [90% confidence interval] with the exception of Tmax,
which is presented as the median (range). The primary outcome was
evaluated against the predefined no-effect range of 0.75–1.33. The
Wilcoxon signed-rank test was used to test for a difference in Tmax.
Differences in AUC0-72h, AUC0-inf, Cmax, t1/2, Cl/F, and AUEC between
treatment groups were analyzed by standard repeated-measures
analysis of variance (a 5 0.05) using log-transformed data.
In Vitro Study. Data are presented as the mean of duplicate
incubations. MBI kinetic parameters are presented as estimates6 S.E.
Results
All Enrolled Subjects Completed the Clinical Study with
Negligible Side Effects
The mean6 S.D. concentration of DHB in the test juice was
73.7 6 4.0 mM, measured in triplicate. Of the 18 potential
subjects screened, 8 men and 8 nonpregnant women were
enrolled. The median (range) age was 29 (22–59) and 40
(29–53) years, respectively. Participants were self-identified as
white (5 men, 4 women), African American (1 man, 4 women),
Hispanic (1 man), or Asian (1 man). None of the subjects
reported taking concomitant medications or dietary substances
known to modulate the metabolism and transport of both
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loperamide and morphine. Concomitant medications included
acetaminophen (2 women) and promethazine (1 woman). All
subjects completed both phases of the study. GFJ and both
drugs were well tolerated; one subject reported mild constipa-
tion with loperamide during the GFJ phase that resolved
within 24 hours.
Grapefruit Juice Increased the Systemic Exposure of
Loperamide with No Effect on Pupil Diameter
Pharmacokinetics. Loperamide and N-desmethyllopera-
mide were detected readily in plasma of all subjects throughout
the 72-hour collection period. Relative to water, GFJ elevated
the plasma concentrations of loperamide but had no effect on
those of N-desmethylloperamide (Fig. 2A). The percentage of
loperamide AUC0-inf extrapolated from 72 hours to infinite time
was always ,25% in both the water and GFJ phases. The pri-
mary outcome, AUCGFJ/AUC, was outside the range associated
with bioequivalence (0.75–1.33) (Table 1). Relative to water,
GFJ increased geometric mean loperamide Cmax, AUC0-72h,
and AUC0-inf significantly, by ∼60–70%; geometric mean Cl/F
decreased significantly, by 43% (Table 1). GFJ had no effect on
geometric mean loperamide terminal t1/2. Median loperamide
Tmax did not differ significantly between treatments. The
percentage of N-desmethylloperamide AUC0-inf extrapolated
from 72 hours to infinite time was.40% in the water and GFJ
phases in 10 of the subjects, precluding accurate recovery of
AUC0-inf, as well as t1/2, in these subjects. As such, geometric
means for these outcomes are not reported. GFJ had no effect
onN-desmethylloperamide geometricmeanCmax and AUC0-72h
and median Tmax; (AUCm/AUCp)0-72h decreased by 40%
(Table 1).
Pharmacodynamics. Relative to baseline, morphine, but
not loperamide, decreased pupil diameter (Fig. 2B). The geo-
metric mean (90% confidence interval [90% CI]) AUEC0-2h and
Rmax for morphine were 150 [115–195] mm*h and 1.9 [1.5–2.5]
mm, respectively. The median (range) time to Rmax was 1.0
(0.5–1.5) hours. The geometric mean [90% confidence interval]
AUEC0-72h for loperamide in the absence and presence of GFJ
was 11.3 [9.2–13.9] and 11.8 [8.5–16.4] mm*h, respectively; the
geometric mean Rmax was 0.38 [0.30–0.47] and 0.40 [0.33–0.51]
mm, respectively.
DHB Is a Mechanism-Based Inhibitor of Loperamide
N-Desmethylation in HIMs
DHB inhibitedN-desmethylloperamide formation in a time-
and concentration-dependent manner in HIMs (Fig. 3). TheKI
and kinact were 5.0 6 0.9 mM and 0.38 6 0.02 minute
21,
respectively. The efficiency of inactivation (kinact/KI) was
76 ml/min per picomole.
DHB Is Predictive of Interactions between Grapefruit Juice
and Loperamide and Several Marketed Drugs
Using DHB as a marker constituent of GFJ and a mecha-
nistic static model, the predicted AUCGFJ/AUC for loperamide
was 1.6. The AUCGFJ/AUC and Fg for other marketed drugs
were obtained from the literature according to predefined
criteria. The reported absolute bioavailability and Fg of these
drugs ranged from 0.12 to 0.94 and 0.14 to 0.94, respectively
(Table 2). Application of the mechanistic static model to these
marketed drugs predicted the AUCGFJ/AUC of 12 of 15
interactions to within the predefined 25% criterion (Fig. 4).
Victim Drug Fg Is More Sensitive than Enterocyte Ig and
Intestinal CYP3A4 kdeg in the Prediction of AUCGFJ/AUC
AUCGFJ/AUC was simulated with varying Ig, Fg, and kdeg to
account for the uncertainty in enterocyte DHB concentration
and variability in victim drug Fg and kdeg. Using loperamide
as an example, of which the estimated Fg was 0.62 (predicted
using the Qgut model in Simcyp), incremental (0.1 mM)
increases in Ig reached a maximum AUCGFJ/AUC (1.6) at
1.2 mM (Fig. 5). The Ig required to achieve the maximum
AUCGFJ/AUC increased with decreasing Fg. An incremental
decrease (0.05) in Fg from 0.90 to 0.45 at a constant Ig (1.2 mM)
resulted in a nearly proportional increase in AUCGFJ/AUC.
Simulated Fg values less than 0.45 resulted in a greater than
proportional increase in AUCGFJ/AUC. Simulations with
varying kdeg showed a minimal effect on AUCGFJ/AUC at
any given Ig or Fg (not shown).
Discussion
Dietary substance–drug interaction risk assessment is
fraught with challenges, adding to those encountered with
DDIs. Dietary substances have a more complex biochemical
makeup than oral drug formulations. Identification of major
constituents (chemical classes or single chemical entities) that
Fig. 2. Loperamide (solid symbols) and N-desmethylloperamide (open
symbols) plasma concentrations (A) and pupil diameter measurements (B)
in 16 healthy volunteers administered loperamide (16 mg) with 240 ml of
water (circles, solid lines) or grapefruit juice (triangles, dashed lines). The
inset depicts the 0- to 2-hour pupil diameter–time profile after loperamide
(in the absence and presence of grapefruit juice) and morphine (diamonds)
administration for the nine volunteers administered themorphine challenge
(0.07 mg/kg i.v.). Symbols and error bars denote the geometric mean and
upper 90% confidence intervals, respectively.
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contribute to inhibition of drug-metabolizing enzymes, as well
as transporters, would help address some of these challenges
(Won et al., 2012; National Center for Complementary and
Alternative Medicine, 2013). Ideally, a single marker constit-
uent would be identified and evaluated using methods similar
to those used during drug development, including in vitro
bioactivity assays, IVIVE, and clinical assessment. An ap-
proach involving a combination of these methods was eval-
uated using the exemplar perpetrator dietary substance GFJ
and the marker constituent DHB.
Loperamide was selected as the test victim drug based on
predefined criteria (Bailey et al., 2013), and a GFJ-loperamide
interaction study had not been described. The present healthy
volunteer study confirmed the interaction, in which the pri-
mary outcome, geometric mean loperamide AUCGFJ/AUC, was
1.7. The lack of effect on loperamide terminal t1/2 was con-
sistent with an interaction limited to the gut, which is typical of
GFJ-drug interactions (Won et al., 2012; Bailey et al., 2013). In
contrast to loperamide, the pharmacokinetics of the primary
CYP3A4-mediated metabolite, N-desmethylloperamide, were
unchanged in the presence of GFJ, which may reflect elimina-
tion rate–limited kinetics and/or more rapid distribution
into peripheral tissues relative to loperamide (Sklerov
et al., 2005). The pharmacokinetics of both loperamide and
N-desmethylloperamide in the absence of GFJ were consis-
tent with those reported at an equivalent (16 mg) (Mukwaya
et al., 2005) or lower (2–4 mg) (Streel et al., 2005; Niemi
et al., 2006) loperamide dose after dose normalization.
Based on anecdotal reports describing loperamide abuse
when taken with GFJ (Daniulaityte et al., 2013) and the ease
of measuring pupil diameter as an index of central nervous
system opiate-like effect, a pharmacodynamic interaction was
assessed. Compared with baseline, the relatively high dose of
loperamide did not produce miosis in either the absence or
presence of GFJ. The lack of miosis was consistent with
previous healthy volunteer studies in which loperamide was
administered at higher doses ($24 mg) (Skarke et al., 2003) or
with potent CYP3A4 or dual CYP3A4/P-glycoprotein (P-gp)
inhibitors (Mukwaya et al., 2005; Niemi et al., 2006).
Confirmation of the GFJ-loperamide interaction permitted
evaluation of a marker constituent predictive of whole juice.
In addition to DHB, the furanocoumarin bergamottin was
considered. Although several furanocoumarins (including dimers
and trimers of DHB and bergamottin) are mechanism-based
inhibitors of CYP3A4, DHB and bergamottin are the most
extensively studied, are readily quantifiable in GFJ, and au-
thentic standards are commercially available. Despite the fact
that bergamottin is a potent mechanism-based inhibitor, this
constituent appears to contribute minimally to the effect in vivo
(Goosen et al., 2004), at least with respect to rapidly absorbed
CYP3A4 substrates (Paine et al., 2005).
MBI kinetic parameters for DHB were confirmed using
pooled HIMs and N-desmethylloperamide formation as the
index reaction to inform a mechanistic static interaction
model specific to the gut. The parameters, KI and kinact
(5.0 mM and 0.38 minute21, respectively), were comparable to
those recovered using other CYP3A4-mediated reactions and
HIMs prepared from a single donor, specifically testosterone
6b-hydroxylation (2.5 mM and 0.40 minute21, respectively)
and midazolam 19-hydroxylation (3.5 mM and 0.31 minute21,
respectively) (Paine et al., 2004). Because MBI appears to
predominate over reversible inhibition, at least with respect
to fruit juices (Hanley et al., 2012), only MBI was considered
TABLE 1
Pharmacokinetic outcomes of loperamide and N-desmethylloperamide in 16 healthy volunteers
administered loperamide (16 mg) with 240 ml of water or GFJ
Values denote the geometric mean (90% confidence intervals) unless indicated otherwise.
Outcome Water GFJ GFJ/Water Ratio
Loperamide
Cmax (nM) 6.5 (5.3–8.1) 10 (8.2–13) 1.58 (1.33–1.88)
a
AUC0-72h (nM · h) 105 (87–126) 180 (149–220) 1.72 (1.58–1.87)
a
AUC0-inf (nM · h) 118 (96–145) 203 (165–250) 1.73 (1.58–1.89)
a
Cl/F (l/h) 285 (232–351) 165 (134–203) 0.57 (0.53–0.62)a
Terminal t1/2 (h) 23.3 (20.7–26.3) 23.2 (20.8–26.0) 1.04 (0.94–1.16)
Tmax (h) [median (range)] 3.0 (0.5–12) 5.0 (2.0–6.0)
b
N-Desmethylloperamide
Cmax (nM) 7.9 (6.7–9.2) 7.7 (6.6–9.0) 0.98 (0.83–1.15)
AUC0-72h (nM · h) 271 (253–290) 290 (270–310) 1.04 (0.99–1.10)
Tmax (h) [median (range)] 5.5 (2.0–12) 7.0 (4.0–26)
b
Metabolite/parent AUC ratio
(AUCm/AUCp)0-72h 2.6 (2.2–3.1) 1.6 (1.3–1.9)
AUCm, AUC of N-desmethylloperamide; AUCp, AUC of loperamide.
aOutside the predefined no-effect range (0.75–1.33).
bNot significant (P , 0.05, Wilcoxon signed-rank test).
Fig. 3. Time- and concentration-dependent inhibition of loperamide
N-desmethylation by DHB in human intestinal microsomes. Symbols
denote the mean of duplicate incubations, all of which deviated by ,20%.
Lines denote linear regression of the initial monoexponential decline; solid
lines denote nonlinear least-squares regression of observed values using
Phoenix WinNonlin (v6.3). The inset depicts the apparent enzyme inac-
tivation rate as a function of DHB concentration.
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for the predictions. The other parameters needed to inform
the model, Fg and Ig, were estimated using literature data.
The Fg for loperamide and Ig for DHB were predicted using
theQgut and ADAMmodels within Simcyp (Yang et al., 2007),
which were informed by permeability data (loperamide and
DHB) (Tran et al., 2004; Paine et al., 2005), metabolic kinetic
data (loperamide) (Kim et al., 2004), and intestinal villous
blood flow. The predicted AUCGFJ/AUCagreedwith the observed
AUCGFJ/AUC (1.6 versus 1.7) to within the 25% predefined
criterion, supporting DHB as a marker constituent predictive of
the CYP3A4-mediated GFJ effect.
The successful IVIVE with the GFJ-loperamide interaction
prompted further evaluation with other previously tested
CYP3A4 drug substrates. Based on the availability of human
pharmacokinetic data and Fg values, 15 interaction studies
were identified. Although the absolute bioavailability of three
of the drugs was relatively high (.70%), and thus were not
victim drugs per se, these drugs were included to provide
a wide range of AUCGFJ/AUCs. The Fg values of the test
drugs, determined from liver transplant patients during the
anhepatic phase of the operation, by combined intravenous
and oral administration, or in vitro–in vivo scaling tech-
niques, ranged from 0.11 to 0.94. Drugs whose Fg values were
determined using GFJ to “knockout” intestinal CYP3A4 were
excluded to avoid bias. The same DHB Ig used for the GFJ-
loperamide interaction prediction was used for the other
victim drugs. As with loperamide, DHB was predictive to
within 25% of the observed AUCGFJ/AUC for 12 of the in-
teractions. The three outlier victim drugs were atorvastatin,
simvastatin, and triazolam. The interaction with atorvastatin
was overpredicted by 3.3-fold (4.0 versus 1.2), which may re-
flect atorvastatin being a substrate for organic anion trans-
porting polypeptide (OATP) 2B1 (Km, 0.2 mM) (Kalliokoski
and Niemi, 2009), an uptake transporter expressed on the
apical membrane of enterocytes and other cell types (Ito et al.,
2005). GFJ has been shown to decrease systemic exposure to
the OATP substrate fexofenadine via inhibition of intestinal
OATP(s) (Dresser et al., 2002). Because inhibition of in-
testinal OATP(s) and CYP3A4 decrease and increase systemic
drug exposure, respectively, these two processes acting in
concert would be expected to reduce the AUCGFJ/AUC
compared with CYP3A4 inhibition alone. Conversely, sub-
strates of both CYP3A4 and the apically located efflux
transporter, P-gp, would be expected to increase the
AUCGFJ/AUC compared with CYP3A4 inhibition alone. The
AUCGFJ/AUC of such dual CYP3A4/P-gp substrates (cyclo-
sporine, methadone, quinidine, tacrolimus) were well pre-
dicted despite reports that DHB inhibits P-gp (Eagling et al.,
1999). This observation suggests that the contribution of
TABLE 2






Estimate Reference Observed Reference
Alfentanil 0.60c Kharasch et al., 2008 0.42d 1.6 Kharasch et al., 2004b
Alprazolam 0.94e Hirota et al., 2001 0.88 6 0.16 1.1 Yasui et al., 2000
Atorvastatin 0.24c Lennernas, 2003 0.12 1.2 Reddy et al., 2011
Buspirone 0.21e Obach et al., 2005 0.40 6 0.04 4.3 Lilja et al., 1998
Cyclosporine 0.28–0.68c Ducharme et al., 1995 0.28 6 0.18 1.4–1.9 Schwarz et al., 2006; Paine et al., 2008
Felodipine 0.45c Lundahl et al., 1997 0.15 6 0.8 2.0 Paine et al., 2006a
Methadone 0.78c Kharasch et al., 2004a 0.92 6 0.21 1.1 Kharasch et al., 2008
Midazolam 0.57f Paine et al., 1996 0.44 6 0.17 1.7 Kharasch et al., 2004b
Nifedipine 0.78c Holtbecker et al., 1996 0.50 6 0.13 1.1 Odou et al., 2005
Nisoldipine 0.11c Gertz et al., 2010 0.05 8.2 Takanaga et al., 2000
Sildenafil 0.78c Gertz et al., 2010 0.38 1.2 Jetter et al., 2002
Simvastatin 0.66e Obach et al., 2006 #0.5 3.6 Lilja et al., 2004
Quinidine 0.90c Darbar et al., 1997 0.71 6 0.17 1.05g Damkier et al., 1999
Tacrolimus 0.14c Floren et al., 1997 0.25 6 0.10 6.6h Liu et al., 2009
Triazolam 0.75c Masica et al., 2004 0.55–0.60i 2.0 Sugimoto et al., 2006
F, oral bioavailability.
aObtained from Brunton et al. (2010) unless indicated otherwise.
bRatio of the area under the plasma concentration–time curve in the presence to absence of grapefruit juice, unless indicated otherwise.
cEstimated using intravenous administration, systemic clearance, and oral bioavailability data.
dObtained from Kharasch et al. (2004a).
eDetermined by in vitro to in vivo extrapolation using in vitro intrinsic clearance data.
fDetermined from anhepatic patients.
gRatio of maximum concentration in the presence to absence of grapefruit juice.
hRatio of trough concentrations in liver transplant recipients following 1 week of treatment and chronic grapefruit juice consumption.
iObtained from Masica et al. (2004).
Fig. 4. Relationship between the predicted and observed AUCGFJ/AUC
for 15 test drug substrates of the “grapefruit juice effect” due to inhibition
of intestinal CYP3A4. Predictions were made using a mechanistic static
model. The solid line denotes unity. Dashed lines denote 25% variability
around the line of unity. Error bars denote predicted values at an Ig of
0.05 mM (lower) and 50 mM (upper, which are smaller than the circles);
circles denote the predicted values at an Ig of 5 mM. Closed circles denote
predictions that were accurate to within 25% of observed values. Open
circles denote predictions that were .25% of observed values.
582 Ainslie et al.
intestinal CYP3A4 inhibition supersedes that of intestinal
P-gp inhibition when GFJ is coadministered with dual CYP3A4/
P-gp substrates.
Unlike with atorvastatin, the interaction with simvastatin
was underpredicted, by a factor of 2.4 (1.5 versus 3.6). Sim-
vastatin was one of three drugs whose Fg was determined using
an in vitro extrapolation technique, which may have overes-
timated Fg, resulting in the underprediction. The method used
to derive simvastatin Fg (0.66) involved oral clinical pharma-
cokinetic and in vitro microsomal clearance data. This estimate
was used in lieu of that obtained with the Qgut model (0.06)
(Gertz et al., 2010), as the former was derived using some
clinical data versus in vitro data alone. The Fg from the Qgut
model would have overpredicted simvastatin AUCGFJ/AUC by
9-fold. The disconnects between the two methods and between
the observed and predicted AUCGFJ/AUC suggest that other
unknownmechanisms/factors contribute to the GFJ-simvastatin
interaction.
As with simvastatin, the interaction with triazolam was
underpredicted, albeit modestly (1.5 versus 2.0), which may
be due to racial and/or sex differences between subjects. The
reference clinical study involved nine healthy Japanese men
(Sugimoto et al., 2006), and the estimated Fg was derived from
healthy Caucasians (10 men, 11 women) (Masica et al., 2004).
In addition, the dose-normalized AUC in the absence of GFJ
was lower in the Japanese study compared with that reported
for American men (11 Caucasians, 2 African Americans)
(Greenblatt et al., 2005). Taken together, the extent of intes-
tinal extraction of triazolam may be greater (i.e., Fg may be
lower) in Japanese than American men, which would explain
the greater AUCGFJ/AUC in the Japanese cohort.
The aforementioned discrepancies highlight limitations of the
IVIVE method used in the current work. First, the accuracy of
the predicted AUCGFJ/AUC is dependent on an accurate victim
drugFg, as themodel is sensitive to this parameter, particularly
when less than 0.45 (Fig. 5). As such, robust methods of
predicting Fg remain critical. Second, significant involvement of
uptake transporters, including OATPs, in the disposition of the
test drugwould preclude use of thismodel, as constituents other
than DHB, including the flavanone glycoside naringin, inhibit
OATPs. Third, this approach cannot account for varying DHB
concentration in GFJ, nor frequency of GFJ administration,
as the relationship between juice DHB concentration and
enterocyte DHB concentration is not yet understood. These
complexities could be addressed using more advanced (dy-
namic) modeling. Despite these limitations, this IVIVE ap-
proach demonstrates DHB as a reasonable marker constituent
to predict the interaction liability of GFJwith candidate CYP3A4
drug substrates. In addition, this straightforward approach,
which could be implemented readily into work streams in
drug discovery programs, could be applied to other dietary
substance–drug interactions upon identification of a candi-
date marker constituent.
In summary, the importance of dietary substance–drug
interaction risk assessment has been recognized, yet system-
atic guidelines have not been established. A framework to
identify marker constituent(s) in dietary substances was ap-
plied in the current work using GFJ as an exemplar per-
petrator, DHB as a candidate constituent, and loperamide as
a test victim drug. A mechanistic static model of intestinal
CYP3A4 MBI incorporating DHB kinetic parameters was
sufficient to predict the GFJ-loperamide interaction, as well
as 12 of 15 previously reported GFJ-drug interaction studies,
to within 25%. This approach has limitations with victim
drugs whose estimated Fg is inaccurate/uncertain and/or are
substrates for intestinal OATPs or other uptake transporters.
This IVIVE method is a relatively simple and cost-effective
means to assess CYP3A4-mediated GFJ-drug interaction lia-
bility or to prioritize compounds for more advanced and
resource-heavy assessment, such as dynamic modeling and/or
clinical evaluation. In conclusion, this IVIVE method expands
upon proposed frameworks to assess clinically relevant dietary
substance–drug interactions, the results of which will help
guide interaction risk assessment.
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